Get the Stockscreener App
7.75
4.32%
-0.35
Pre-market:
7.90
0.15
+1.94%
ImmunityBio Inc stock is currently priced at $7.75, with a 24-hour trading volume of 4.85M.
It has seen a -4.32% decreased in the last 24 hours and a +57.52% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $8.24 pivot point. If it approaches the $7.47 support level, significant changes may occur.
Previous Close:
$8.10
Open:
$8.06
24h Volume:
4.85M
Market Cap:
$5.36B
Revenue:
$622.00K
Net Income/Loss:
$-583.20M
P/E Ratio:
-6.7982
EPS:
-1.14
Net Cash Flow:
$-397.34M
1W Performance:
-3.85%
1M Performance:
+57.52%
6M Performance:
+89.49%
1Y Performance:
+134.14%
1D Range:
$7.65
$8.1612
52W Range:
$1.25
$10.53
ImmunityBio Inc Stock (IBRX) Company Profile
Name
ImmunityBio Inc
Sector
Industry
Phone
310 883 1300
Address
2040 E MARIPOSA AVENUE, El Segundo
ImmunityBio Inc Stock (IBRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-03-22 | Initiated | Jefferies | Buy |
ImmunityBio Inc Stock (IBRX) Latest News
ImmunityBio (NASDAQ:IBRX) Shares Down 4.2% - MarketBeat
MarketBeat
Investigation Alert Baxter International, Eagle Pharmaceuticals, BioXcel Therapeutics, and ImmunityBio: - EIN News
EIN News
ImmunityBio (NASDAQ:IBRX) Trading Up 8.9% - MarketBeat
MarketBeat
Amid Biotech Pitfalls, this Stock Has Outperformed NVDA in the Last 3 Months - The Tokenist
The Tokenist
ImmunityBio Advances On the Anktiva Front - Los Angeles Business Journal
Los Angeles Business Journal
ImmunityBio First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Yahoo Finance
ImmunityBio Inc Stock (IBRX) Financials Data
ImmunityBio Inc (IBRX) Revenue 2024
IBRX reported a revenue (TTM) of $622.00 thousand for the quarter ending December 31, 2023, a +159.17% rise year-over-year.
ImmunityBio Inc (IBRX) Net Income 2024
IBRX net income (TTM) was -$583.20 million for the quarter ending December 31, 2023, a -40.00% decrease year-over-year.
ImmunityBio Inc (IBRX) Cash Flow 2024
IBRX recorded a free cash flow (TTM) of -$397.34 million for the quarter ending December 31, 2023, a +9.05% increase year-over-year.
ImmunityBio Inc (IBRX) Earnings per Share 2024
IBRX earnings per share (TTM) was -$1.16 for the quarter ending December 31, 2023, a -10.48% decline year-over-year.
About ImmunityBio Inc
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to combat multiple tumor types without the use of high-dose chemotherapy. It develops an albumin-linked chemotherapeutic therapy (Aldoxorubicin), a novel IL-15 cytokine superagonist (N-803), checkpoint inhibitors, macrophage polarizing peptides, bi-specific fusion proteins targeting TGFb and IL-12, adenovirus, and yeast vaccine therapies targeting tumor-associated antigens and neoepitopes. ImmunityBio, Inc. was formerly known as NantCell, Inc. and changed its name to ImmunityBio, Inc. in June 2019. The company was incorporated in 2014 and is based in El Segundo, California. ImmunityBio, Inc. operates as a subsidiary of NantWorks, LLC.
4.27%
2.59%
Cap:
|
Volume (24h):